Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ABBV.MX
- Price
- 4022.00
- Stock movement down
- -197.00 (-4.67%)
- Company name
- AbbVie Inc
- Exchange
- (MX ,
- Currency
- MXN )
- Sector
- Healthcare >Drug Manufacturers - General
- Market cap
- 7108.42B
- Ent value
- 7239.29B
- Price/Sales
- 119.18
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 2976.73
- Forward P/E
- -
- PEG
- -
- EPS growth
- -14.58%
- 1 year return
- 13.61%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
ABBV.MX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 2976.73 |
| Price to OCF | 340.77 |
| Price to FCF | 361.13 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 119.18 |
| Price to Book | - |
| EV to Sales | 121.38 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.77B |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.63B |
| Net receivables | 12.77B |
| Total current assets | 28.54B |
| Goodwill | 35.63B |
| Intangible assets | 54.31B |
| Property, plant and equipment | 13.23B |
| Total assets | 133.90B |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 39.39B |
| Total liabilities | 136.50B |
| Shareholder's equity | -2.60B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4078.74 |
| Daily high | 4078.74 |
| Daily low | 4022.00 |
| Daily Volume | 1K |
| All-time high | 4481.27 |
| 1y analyst estimate | - |
| Beta | 0.35 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 15 Oct 2025 |
| Next earnings date | 6 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ABBV.MX | S&P500 | |
| Current price drop from All-time high | -10.25% | - |
| Highest price drop | -24.56% | -19.00% |
| Date of highest drop | 21 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -11.16% | -2.64% |
| Avg time to new high | 16 days | 6 days |
| Max time to new high | 142 days | 89 days |
COMPANY DETAILS
Marketcap
7108.42B
Marketcap category
Large-cap
Description
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
55000
Website
Investor relations
-
SEC filings
CEO
Country
Mexico
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly results, higher earnings guidance, and another dividend increase. See our ...
December 13, 2025
These habitual market beaters can pull it off again.
December 13, 2025
Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business ...
December 13, 2025
They could grow into their valuation over the next few years.
December 12, 2025
Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course. Among thousands o...
December 12, 2025
AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.
December 12, 2025
AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026
December 12, 2025
See what solid dividends do for a portfolio after just five years.
December 12, 2025
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing mar...
December 12, 2025
The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopha...
December 11, 2025
Next page